514 results on '"McMullen, Julie R."'
Search Results
152. Class I A Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy
- Author
-
Luo, Ji, primary, McMullen, Julie R., additional, Sobkiw, Cassandra L., additional, Zhang, Li, additional, Dorfman, Adam L., additional, Sherwood, Megan C., additional, Logsdon, M. Nicole, additional, Horner, James W., additional, DePinho, Ronald A., additional, Izumo, Seigo, additional, and Cantley, Lewis C., additional
- Published
- 2005
- Full Text
- View/download PDF
153. Deletion of Ribosomal S6 Kinases Does Not Attenuate Pathological, Physiological, or Insulin-Like Growth Factor 1 Receptor-Phosphoinositide 3-Kinase-Induced Cardiac Hypertrophy
- Author
-
McMullen, Julie R., primary, Shioi, Tetsuo, additional, Zhang, Li, additional, Tarnavski, Oleg, additional, Sherwood, Megan C., additional, Dorfman, Adam L., additional, Longnus, Sarah, additional, Pende, Mario, additional, Martin, Kathleen A., additional, Blenis, John, additional, Thomas, George, additional, and Izumo, Seigo, additional
- Published
- 2004
- Full Text
- View/download PDF
154. Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload
- Author
-
McMullen, Julie R., primary, Sherwood, Megan C., additional, Tarnavski, Oleg, additional, Zhang, Li, additional, Dorfman, Adam L., additional, Shioi, Tetsuo, additional, and Izumo, Seigo, additional
- Published
- 2004
- Full Text
- View/download PDF
155. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies
- Author
-
Tarnavski, Oleg, primary, McMullen, Julie R., additional, Schinke, Martina, additional, Nie, Qing, additional, Kong, Sekwon, additional, and Izumo, Seigo, additional
- Published
- 2004
- Full Text
- View/download PDF
156. The Insulin-like Growth Factor 1 Receptor Induces Physiological Heart Growth via the Phosphoinositide 3-Kinase(p110α) Pathway
- Author
-
McMullen, Julie R., primary, Shioi, Tetsuo, additional, Huang, Weei-Yuarn, additional, Zhang, Li, additional, Tarnavski, Oleg, additional, Bisping, Egbert, additional, Schinke, Martina, additional, Kong, Sekwon, additional, Sherwood, Megan C., additional, Brown, Jeffrey, additional, Riggi, Lauren, additional, Kang, Peter M., additional, and Izumo, Seigo, additional
- Published
- 2004
- Full Text
- View/download PDF
157. Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice
- Author
-
Shioi, Tetsuo, primary, McMullen, Julie R., additional, Tarnavski, Oleg, additional, Converso, Kimber, additional, Sherwood, Megan C., additional, Manning, Warren J., additional, and Izumo, Seigo, additional
- Published
- 2003
- Full Text
- View/download PDF
158. 125I[Sar1Ile8] Angiotensin II has a different affinity for AT1 and AT2 receptor subtypes in ovine tissues
- Author
-
McMullen, Julie R, primary, Gibson, Karen J, additional, Lumbers, Eugenie R, additional, and Burrell, Judith H, additional
- Published
- 2002
- Full Text
- View/download PDF
159. Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice
- Author
-
Shioi, Tetsuo, primary, McMullen, Julie R., additional, Kang, Peter M., additional, Douglas, Pamela S., additional, Obata, Toshiyuki, additional, Franke, Thomas F., additional, Cantley, Lewis C., additional, and Izumo, Seigo, additional
- Published
- 2002
- Full Text
- View/download PDF
160. Selective down-regulation of AT2 receptors in uterine arteries from pregnant ewes given 24-h intravenous infusions of angiotensin II
- Author
-
McMullen, Julie R, primary, Gibson, Karen J, additional, Lumbers, Eugenie R, additional, and Burrell, Judith H, additional
- Published
- 2001
- Full Text
- View/download PDF
161. Micro RNAs differentially regulated in cardiac and skeletal muscle in health and disease: Potential drug targets?
- Author
-
Winbanks, Catherine E, Ooi, Jenny YY, Nguyen, Sally S, McMullen, Julie R, and Bernardo, Bianca C
- Subjects
RIBONUCLEASES ,SKELETAL muscle ,MYOCARDIUM ,DNA ,RNA - Abstract
The identification of non-coding RNA species, previously thought of as 'junk' DNA, adds a new dimension of complexity to the regulation of DNA, RNA and protein. Micro RNAs are short non-coding RNA species that control gene expression, are dysregulated in settings of cardiac and skeletal muscle disease and have emerged as promising therapeutic targets. Micro RNAs specifically enriched in cardiac and skeletal muscle are called myomiRs and play an important role in cardiac pathology and skeletal muscle biology. Moreover, micro RNA profiles are altered in response to exercise and disease; thus, their potential as therapeutic drug targets is being widely explored. In the cardiovascular field, therapeutic inhibition of micro RNAs has been shown to be effective in improving cardiac outcome in preclinical cardiac disease models. Micro RNAs that promote skeletal muscle regeneration are attractive therapeutic targets in muscle wasting conditions where regenerative capacity is compromised. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
162. Interactions between AT1 and AT2 receptors in uterine arteries from pregnant ewes
- Author
-
McMullen, Julie R, primary, Gibson, Karen J, additional, Lumbers, Eugenie R, additional, Burrell, Judith H, additional, and Wu, June, additional
- Published
- 1999
- Full Text
- View/download PDF
163. Effects of Intravenous Infusions of Noradrenaline on Renal Function in Chronically Catheterised Fetal Sheep
- Author
-
McMullen, Julie R., primary, Gibson, Karen J., additional, and Lumbers, Eugenie R., additional
- Published
- 1998
- Full Text
- View/download PDF
164. No Contribution of IP3-R(2) to Disease Phenotype in Models of Dilated Cardiomyopathy or Pressure Overload Hypertrophy.
- Author
-
Cooley, Nicola, Ouyang, Kunfu, McMullen, Julie R., Kiriazis, Helen, Sheikh, Farah, Wu, Wei, Mu, Yongxin, Du, Xiao-Jun, Chen, Ju, and Woodcock, Elizabeth A.
- Abstract
We investigated the contribution of inositol(1,4,5)-trisphosphate (Ins(1,4,5)P
3 [IP3 ]) receptors (IP3 -R) to disease progression in mouse models of dilated cardiomyopathy (DCM) and pressure overload hypertrophy. Mice expressing mammalian sterile 20-like kinase and dominant-negative phosphatidylinositol-3-kinase in heart (Mst1×dn-PI3K-2Tg; DCM-2Tg) develop severe DCM and conduction block, associated with increased expression of type 2 IP3 -R (IP3 -R(2)) and heightened generation of Ins(1,4,5)P3 . Similar increases in Ins(1,4,5)P3 and IP3 -R(2) are caused by transverse aortic constriction.To evaluate the contribution of IP3 -R(2) to disease progression, the DCM-2Tg mice were further crossed with mice in which the type 2 IP3 -R (IP3 -R(2)-/-) had been deleted (DCM-2Tg×IP3 -R(2)-/-) and transverse aortic constriction was performed on IP3 -R(2)-/- mice. Hearts from DCM-2Tg mice and DCM-2Tg×IP3 -R(2)-/- were similar in terms of chamber dilatation, atrial enlargement, and ventricular wall thinning. Electrophysiological changes were also similar in the DCM-2Tg mice, with and without IP3 -R(2). Deletion of IP3 -R(2) did not alter the progression of heart failure, because DCM-2Tg mice with and without IP3 -R(2) had similarly reduced contractility, increased lung congestion, and atrial thrombus, and both strains died between 10 and 12 weeks of age. Loss of IP3 -R(2) did not alter the progression of hypertrophy after transverse aortic constriction.We conclude that IP3 -R(2) do not contribute to the progression of DCM or pressure overload hypertrophy, despite increased expression and heightened generation of the ligand, Ins(1,4,5)P3 . [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
165. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism.
- Author
-
Tuanzhu Ha, Fang Hua, Xiang Liu, Jing Ma, McMullen, Julie R., Shioi, Tetsuo, Izumo, Seigo, Kelley, Jim, Gao, Xiag, Browder, William, Williams, David L., Kao, Race L., and Chuanfu Li
- Subjects
ISCHEMIA ,REPERFUSION injury ,PHOSPHOINOSITIDES ,PHOSPHOLIPIDS ,BLOOD circulation disorders - Abstract
Aims: The ability of lipopolysaccharide (LPS) pre-treatment to induce cardioprotection following ischaemia/reperfusion (I/R) has been well documented; however, the mechanisms have not been fully elucidated. LPS is a Toll-like receptor 4 (TLR4) ligand. Recent evidence indicates that there is cross-talk between the TLR and phosphoinositide 3-kinase/Akt (PI3K/Akt) signalling pathways. We hypothesized that activation of PI3K/Akt signalling plays a critical role in LPS-induced cardioprotection. [ABSTRACT FROM PUBLISHER]
- Published
- 2008
- Full Text
- View/download PDF
166. PI3K (p110α) Inhibitors as Anti-Cancer Agents.
- Author
-
McMullen, Julie R. and Jay, Patrick Y.
- Published
- 2007
- Full Text
- View/download PDF
167. Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy.
- Author
-
McMullen, Julie R., Amirahmadi, Fatemeh, Woodcock, Elizabeth A., Schinke-Braun, Martina, Bouwman, Russell D., Hewitt, Kimberly A., Mollica, Janelle P., Li Zhang, Yunyu Zhang, Tetsuo Shioi, Buerger, Antje, Izumo, Seigo, Jay, Patrick V., and Jennings, Garry L.
- Subjects
- *
HEART failure , *HEART diseases , *GENETIC transduction , *CARDIAC hypertrophy , *EXERCISE , *PHYSICAL education - Abstract
Physical activity protects against cardiovascular disease, and physiological cardiac hypertrophy associated with regular exercise is usually beneficial, in marked contrast to pathological hypertrophy associated with disease. The p110α isoform of phosphoinositide 3-kinase (PI3K) plays a critical role in the induction of exercise-induced hypertrophy. Whether it or other genes activated in the athlete's heart might have an impact on cardiac function and survival in a setting of heart failure is unknown. To examine whether progressive exercise training and PI3K(p110α) activity affect survival and/or cardiac function in two models of heart disease, we subjected a transgenic mouse model of dilated cardiomyopathy (DCM) to swim training, genetically crossed cardiac-specific transgenic mice with increased or decreased PI3K(p110α) activity to the DCM model, and subjected PI3K(p110α)transgenics to acute pressure overload (ascending aortic constriction). Lifespan, cardiac function, and molecular markers of pathological hypertrophy were examined. Exercise training and increased cardiac PI3K(p110α) activity prolonged survival in the DCM model by 15–20%. In contrast, reduced PI3K(p110α) activity drastically shortened lifespan by ≈50%. Increased PI3K(p110α) activity had a favorable effect on cardiac function and fibrosis in the pressure-overload model and attenuated pathological growth. PI3K(p110α) signaling negatively regulated G protein-coupled receptor stimulated extracellular responsive kinase and Akt (via PI3K, p110γ) activation in isolated cardiomyocytes. These findings suggest that exercise and enhanced PI3K(p110α) activity delay or prevent progression of heart disease, and that supraphysiologic activity can be beneficial. Identification of genes important for hypertrophy in the athlete's heart could offer new strategies for treating heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
168. Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure.
- Author
-
Bisping, Egbert, Ikeda, Sadakatsu, Sek Won Kong, Tarnavski, Oleg, Bodyak, Natalya, McMullen, Julie R., Rajagopal, Satish, Son, Jennifer K., Qing Ma, Springer, Zhangli, Kang, Peter M., Izumo, Seigo, and Pu, William T.
- Subjects
HEART failure ,CARDIAC hypertrophy ,GENES ,GENE expression ,APOPTOSIS ,HEART cells - Abstract
An important event in the pathogenesis of heart failure is the development of pathological cardiac hypertrophy. In cultured cardiomyocytes, the transcription factor Gata4 is required for agonist-induced hypertrophy. We hypothesized that, in the intact organism, Gata4 is an important regulator of postnatal heart function and of the hypertrophic response of the heart to pathological stress. To test this hypothesis, we studied mice heterozygous for deletion of the second exon of Gata4 (G4D). At baseline, G4D mice had mild systolic and diastolic dysfunction associated with reduced heart weight and decreased cardiomyocyte number. After transverse aortic constriction (TAC), G4D mice developed overt heart failure and eccentric cardiac hypertrophy, associated with significantly increased fibrosis and cardiomyocyte apoptosis. Inhibition of apoptosis by overexpression of the insulin-like growth factor 1 receptor prevented TAC-induced heart failure in G4D mice. Unlike WT-TAC controls, G4D-TAC cardiomyocytes hypertrophied by increasing in length more than width. Gene expression profiling revealed up-regulation of genes associated with apoptosis and fibrosis, including members of the TGF-β pathway. Our data demonstrate that Gata4 is essential for cardiac function in the postnatal heart. After pressure overload, Gata4 regulates the pattern of cardiomyocyte hypertrophy and protects the heart from load-induced failure. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
169. Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy.
- Author
-
Ji Luo, McMullen, Julie R., Sobkiw, Cassandra L., Li Zhang, Dorfman, Adam L., Sherwood, Megan C., Logsdon, M. Nicole, Homer, James W., DePinho, Ronald A., Izumo, Seigo, and Cantley, Lewis C.
- Subjects
- *
HEART disease genetics , *HISTOPATHOLOGY , *PHOSPHOINOSITIDES , *GENETIC regulation , *PHOSPHOLIPIDS , *GROWTH factors , *HEART diseases , *TRANSGENIC mice - Abstract
Class IA phosphoinositide 3-kinases (PI3Ks) arc activated by growth factor receptors, and they regulate, among other processes, cell growth and organ size. Studies using transgenic mice overexpressing constitutively active and dominant negative forms of the p110α catalytic subunit of class IA PDK have implicated the role of this enzyme in regulating heart size and physiological cardiac hypertrophy. To further understand the role of class IA PI3K in controlling heart growth and to circumvent potential complications from the overexpression of dominant negative and constitutively active proteins, we generated mice with muscle-specific deletion of the p85α regulatory subunit and germ line deletion of the p85β regulatory subunit of class IA PI3K. Here we show that mice with cardiac deletion of both p85 subunits exhibit attenuated Akt signaling in the heart, reduced heart size, and altered cardiac gene expression. Furthermore, exercise-induced cardiac hypertrophy is also attenuated in the p85 knockout hearts. Despite such defects in postnatal developmental growth and physiological hypertrophy, the p85 knockout hearts exhibit normal contractility and myocardial histology. Our results therefore provide strong genetic evidence that class IA PI3Ks are critical regulators for the developmental growth and physiological hypertrophy of the heart. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
170. Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy.
- Author
-
McMullen, Julie R., Shioi, Tetsuo, Li Zhang, Tarnavski, Oleg, Sherwood, Megan C., Kang, Peter M., and Seigo Izumo
- Subjects
- *
CARDIAC hypertrophy , *GENE expression , *TRANSGENIC mice , *PATHOLOGY - Abstract
An unresolved question in cardiac biology is whether distinct signaling pathways are responsible for the development of pathological and physiological cardiac hypertrophy in the adult. Physiological hypertrophy is characterized by a normal organization of cardiac structure and normal or enhanced cardiac function, whereas pathological hypertrophy is associated with an altered pattern of cardiac gene expression, fibrosis, cardiac dysfunction, and increased morbidity and mortality. The elucidation of signaling cascades that play distinct roles in these two forms of hypertrophy will be critical for the development of more effective strategies to treat heart failure. We examined the role of the p110α isoform of phosphoinositide 3-kinase (PI3K) for the induction of pathological hypertrophy (pressure overload-induced) and physiological hypertrophy (exercise-induced) by using transgenic mice expressing a dominant negative (dn) P13K(p110α) mutant specifically in the heart, dnPI3K transgenic mice displayed significant hypertrophy in response to pressure overload but not exercise training, dnPl3K transgenic mice also showed significant dilation and cardiac dysfunction in response to pressure overload. Thus, PI3K(p110α) appears to play a critical role for the induction of physiological cardiac growth but not pathological growth. PI3K(p110α) also appears essential for maintaining contractile function in response to pathological stimuli. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
171. 125I[Sar1Ile8] Angiotensin II has a different affinity for AT1 and AT2 receptor subtypes in ovine tissues
- Author
-
McMullen, Julie R., Gibson, Karen J., Lumbers, Eugenie R., and Burrell, Judith H.
- Subjects
- *
ANGIOTENSIN II , *CELL receptors - Abstract
Iodinated angiotensin II (Ang II) and its analogues are often assumed to have equal affinities for AT1 and AT2 receptor subtypes. However, using saturation and competition binding assays in several tissues from pregnant, nonpregnant, and fetal sheep, we found the affinity of 125I[Sar1Ile8] Ang II for Ang II receptors was different (P<0.05) between tissue types. The dissociation constants (Kd) and half maximal displacements of [Sar1Ile8] Ang II (Sar IC50) were directly related (P<0.05) to proportions of AT1 receptors, and inversely related (P<0.05) to proportions of AT2 receptors in tissues from all groups combined, in tissues from individual groups (pregnant, nonpregnant or fetal), and in some individual tissues (uterine arteries and aortae). This suggests that 125I[Sar1Ile8] Ang II has a different affinity for AT1 and AT2 receptors in ovine tissues. The Kds of 125I[Sar1Ile8] Ang II for “pure” populations of AT1 and AT2 receptors were 1.2 and 0.3 nM, respectively, i.e. affinity was four-fold higher for AT2 receptors. We corrected the measured proportions of the receptor subtypes using their fractional occupancies. In tissues which contained at least 10% of each receptor subtype, the corrected proportions were significantly altered (P<0.05), even in some tissues, to the extent of being reversed. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
172. Let's keep running... exercise, basic science and the knowledge gaps.
- Author
-
La Gerche, André and McMullen, Julie R.
- Subjects
- *
EXERCISE physiology , *PHYSICAL activity , *PREVENTION of chronic diseases , *HEALTH , *CANCER prevention , *PHYSIOLOGY - Abstract
The article focuses on various aspects related to exercise and physical activity. It states that exercise not only helps in preventing cancer, chronic disease and disability, but also provide overall mortality benefit to the individuals. It mentions that advancements in study of molecular pathways has shown that exercise also affects cardiovascular health of an individual. It also presents certain limitations in the exercise science, such as exercise not being a binary intervention.
- Published
- 2015
- Full Text
- View/download PDF
173. Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation.
- Author
-
Yi Ching Chen, Wijekoon, Seka, Matsumoto, Aya, Jieting Luo, Kiriazis, Helen, Masterman, Emma, Yildiz, Gunes, Cross, Jonathon, Parslow, Adam C., Chooi, Roger, Sadoshima, Junichi, Greening, David W., Weeks, Kate L., and McMullen, Julie R.
- Subjects
- *
INSULIN-like growth factor receptors , *SOMATOMEDIN C , *HEART failure , *ATRIAL fibrillation , *HEART fibrosis - Abstract
Atrial fibrillation (AF) remains challenging to prevent and treat. A key feature of AF is atrial enlargement. However, not all atrial enlargement progresses to AF. Atrial enlargement in response to physiological stimuli such as exercise is typically benign and reversible. Understanding the differences in atrial function and molecular profile underpinning pathological and physiological atrial remodelling will be critical for identifying new strategies for AF. The discovery of molecular mechanisms responsible for pathological and physiological ventricular hypertrophy has uncovered new drug targets for heart failure. Studies in the atria have been limited in comparison. Here, we characterised mouse atria from (1) a pathological model (cardiomyocyte-specific transgenic (Tg) that develops dilated cardiomyopathy [DCM] and AF due to reduced protective signalling [PI3K]; DCM-dnPI3K), and (2) a physiological model (cardiomyocyte-specific Tg with an enlarged heart due to increased insulin-like growth factor 1 receptor; IGF1R). Both models presented with an increase in atrial mass, but displayed distinct functional, cellular, histological and molecular phenotypes. Atrial enlargement in the DCM-dnPI3K Tg, but not IGF1R Tg, was associated with atrial dysfunction, fibrosis and a heart failure gene expression pattern. Atrial proteomics identified protein networks related to cardiac contractility, sarcomere assembly, metabolism, mitochondria, and extracellular matrix which were differentially regulated in the models; many co-identified in atrial proteomics data sets from human AF. In summary, physiological and pathological atrial enlargement are associated with distinct features, and the proteomic dataset provides a resource to study potential new regulators of atrial biology and function, drug targets and biomarkers for AF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
174. No Contribution of IP3-R(2) to Disease Phenotype in Models of Dilated Cardiomyopathy or Pressure Overload Hypertrophy
- Author
-
Cooley, Nicola, Ouyang, Kunfu, McMullen, Julie R., Kiriazis, Helen, Sheikh, Farah, Wu, Wei, Mu, Yongxin, Du, Xiao-Jun, Chen, Ju, and Woodcock, Elizabeth A.
- Abstract
We investigated the contribution of inositol(1,4,5)-trisphosphate (Ins(1,4,5)P3IP3) receptors (IP3-R) to disease progression in mouse models of dilated cardiomyopathy (DCM) and pressure overload hypertrophy. Mice expressing mammalian sterile 20–like kinase and dominant-negative phosphatidylinositol-3-kinase in heart (Mst1×dn-PI3K-2Tg; DCM-2Tg) develop severe DCM and conduction block, associated with increased expression of type 2 IP3-R (IP3-R(2)) and heightened generation of Ins(1,4,5)P3. Similar increases in Ins(1,4,5)P3and IP3-R(2) are caused by transverse aortic constriction.
- Published
- 2013
- Full Text
- View/download PDF
175. Effects of Intravenous Infusions of Noradrenaline on Renal Function in Chronically Catheterised Fetal Sheep.
- Author
-
McMullen, Julie R., Gibson, Karen J., and Lumbers, Eugenie R.
- Published
- 1998
- Full Text
- View/download PDF
176. Old Drug, New Trick: Tilorone, a Broad-Spectrum Antiviral Drug as a Potential Anti-Fibrotic Therapeutic for the Diseased Heart.
- Author
-
Horlock, Duncan, Kaye, David M., Winbanks, Catherine E., Gao, Xiao-Ming, Kiriazis, Helen, Donner, Daniel G., Gregorevic, Paul, McMullen, Julie R., Bernardo, Bianca C., and de Sousa, Maria Emília
- Subjects
ANTIVIRAL agents ,GENE expression profiling ,HEART fibrosis ,HUMAN behavior ,HEART ,HEART failure - Abstract
Cardiac fibrosis is associated with most forms of cardiovascular disease. No reliable therapies targeting cardiac fibrosis are available, thus identifying novel drugs that can resolve or prevent fibrosis is needed. Tilorone, an antiviral agent, can prevent fibrosis in a mouse model of lung disease. We investigated the anti-fibrotic effects of tilorone in human cardiac fibroblasts in vitro by performing a radioisotopic assay for [
3 H]-proline incorporation as a proxy for collagen synthesis. Exploratory studies in human cardiac fibroblasts treated with tilorone (10 µM) showed a significant reduction in transforming growth factor-β induced collagen synthesis compared to untreated fibroblasts. To determine if this finding could be recapitulated in vivo, mice with established pathological remodelling due to four weeks of transverse aortic constriction (TAC) were administered tilorone (50 mg/kg, i.p) or saline every third day for eight weeks. Treatment with tilorone was associated with attenuation of fibrosis (assessed by Masson's trichrome stain), a favourable cardiac gene expression profile and no further deterioration of cardiac systolic function determined by echocardiography compared to saline treated TAC mice. These data demonstrate that tilorone has anti-fibrotic actions in human cardiac fibroblasts and the adult mouse heart, and represents a potential novel therapy to treat fibrosis associated with heart failure. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
177. Nectin-2: an intercalated disc protein that maintains cardiac function in a setting of pressure overload.
- Author
-
McMullen, Julie R.
- Abstract
The article discusses research on the role of nectin-2 in cardiac function. It references a study by S. Satomi-Kobayashi et al published in a 2009 issue of the journal "Hypertension." The authors found that the fall in connexin43 expression was not sufficient to induce arrhythmia under basal conditions. The research shows that nectin-2 plays an important role in protecting the heart against cardiac dysfunction in response to pressure overload but is not necessary under physiological conditions.
- Published
- 2009
- Full Text
- View/download PDF
178. Author Correction: PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
- Author
-
Yoon, Somy, Kook, Taewon, Min, Hyun-Ki, Kwon, Duk-Hwa, Cho, Young Kuk, Kim, Mira, Shin, Sera, Joung, Hosouk, Jeong, Seung Hoon, Lee, Sumin, Kang, Gaeun, Park, Yunchul, Kim, Yong Sook, Ahn, Youngkeun, McMullen, Julie R., Gergs, Ulrich, Neumann, Joachim, Kim, Kyung Keun, Kim, Jungchul, and Nam, Kwang-Il
- Published
- 2019
- Full Text
- View/download PDF
179. PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
- Author
-
Yoon, Somy, Kook, Taewon, Min, Hyun-Ki, Kwon, Duk-Hwa, Cho, Young Kuk, Kim, Mira, Shin, Sera, Joung, Hosouk, Jeong, Seung Hoon, Lee, Sumin, Kang, Gaeun, Park, Yunchul, Kim, Yong Sook, Ahn, Youngkeun, McMullen, Julie R., Gergs, Ulrich, Neumann, Joachim, Kim, Kyung Keun, Kim, Jungchul, and Nam, Kwang-Il
- Published
- 2018
- Full Text
- View/download PDF
180. Clusterin is regulated by IGF1–PI3K signaling in the heart: implications for biomarker and drug target discovery, and cardiotoxicity.
- Author
-
Bass-Stringer, Sebastian, Ooi, Jenny Y. Y., and McMullen, Julie R.
- Subjects
- *
CLUSTERIN , *DRUG target , *CARDIOTOXICITY , *CARDIAC hypertrophy , *TRANSGENIC mice , *DRUG toxicity - Abstract
Open-access gene expression data sets provide a useful resource for identifying novel drug targets and biomarkers. The IGF1–PI3K pathway is a critical mediator of physiological cardiac enlargement/hypertrophy and protection. This study arose after mining a gene microarray data set from a previous study that compared heart tissue from cardiac-specific PI3K transgenic mouse models. The top-ranked candidate identified from the microarray data was clusterin. Clusterin has been proposed as a biomarker for multiple diseases including heart failure, and as a cancer drug target. Here, we show that clusterin gene expression is increased in hearts of transgenic mice with increased PI3K and decreased in mice with depressed cardiac PI3K. In vitro, clusterin secretion was elevated in media from neonatal rat ventricular myocytes treated with IGF1. Furthermore, by mining gene expression data from hearts during normal mouse postnatal growth, we also report an increase in clusterin expression with postnatal heart growth. Given we show that clusterin is regulated by the IGF1–PI3K pathway in the heart, and this pathway mediates physiological cardiac hypertrophy and cardioprotection, caution is required when considering clusterin as a biomarker for heart failure and as a cancer target. Mining pre-existing cardiac profiling data sets may be a useful approach to assess whether regulating new drug targets is likely to lead to cardiac damage/toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
181. A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology.
- Author
-
Weeks, Kate L., Kiriazis, Helen, Wadley, Glenn D., Masterman, Emma I., Sergienko, Nicola M., Raaijmakers, Antonia J. A., Trewin, Adam J., Harmawan, Claudia A., Yildiz, Gunes S., Liu, Yingying, Drew, Brian G., Gregorevic, Paul, Delbridge, Lea M. D., McMullen, Julie R., and Bernardo, Bianca C.
- Subjects
- *
GENE therapy , *GENE targeting , *MOLECULAR pathology , *ACYL coenzyme A , *GENETIC vectors , *DEHYDROGENASES - Abstract
Diabetic cardiomyopathy describes heart disease in patients with diabetes who have no other cardiac conditions but have a higher risk of developing heart failure. Specific therapies to treat the diabetic heart are limited. A key mechanism involved in the progression of diabetic cardiomyopathy is dysregulation of cardiac energy metabolism. The aim of this study was to determine if increasing the expression of medium-chain acyl-coenzyme A dehydrogenase (MCAD; encoded by Acadm), a key regulator of fatty acid oxidation, could improve the function of the diabetic heart. Male mice were administered streptozotocin to induce diabetes, which led to diastolic dysfunction 8 weeks post-injection. Mice then received cardiac-selective adeno-associated viral vectors encoding MCAD (rAAV6:MCAD) or control AAV and were followed for 8 weeks. In the non-diabetic heart, rAAV6:MCAD increased MCAD expression (mRNA and protein) and increased Acadl and Acadvl, but an increase in MCAD enzyme activity was not detectable. rAAV6:MCAD delivery in the diabetic heart increased MCAD mRNA expression but did not significantly increase protein, activity, or improve diabetes-induced cardiac pathology or molecular metabolic and lipid markers. The uptake of AAV viral vectors was reduced in the diabetic versus non-diabetic heart, which may have implications for the translation of AAV therapies into the clinic. Key messages: The effects of increasing MCAD in the diabetic heart are unknown. Delivery of rAAV6:MCAD increased MCAD mRNA and protein, but not enzyme activity, in the non-diabetic heart. Independent of MCAD enzyme activity, rAAV6:MCAD increased Acadl and Acadvl in the non-diabetic heart. Increasing MCAD cardiac gene expression alone was not sufficient to protect against diabetes-induced cardiac pathology. AAV transduction efficiency was reduced in the diabetic heart, which has clinical implications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
182. Cardiovascular magnetic resonance imaging for sequential assessment of cardiac fibrosis in mice: technical advancements and reverse translation.
- Author
-
Yi Ching Chen, Gang Zheng, Donner, Daniel G., Wright, David K., Greenwood, John P., Marwick, Thomas H., and McMullen, Julie R.
- Subjects
- *
CARDIAC magnetic resonance imaging , *HEART fibrosis , *HEART failure , *PULMONARY fibrosis , *MAGNETIC resonance imaging , *HEART diseases - Abstract
Cardiovascular magnetic resonance (CMR) imaging has become an essential technique for the assessment of cardiac function and morphology, and is now routinely used to monitor disease progression and intervention efficacy in the clinic. Cardiac fibrosis is a common characteristic of numerous cardiovascular diseases and often precedes cardiac dysfunction and heart failure. Hence, the detection of cardiac fibrosis is important for both early diagnosis and the provision of guidance for interventions/therapies. Experimental mouse models with genetically and/or surgically induced disease have been widely used to understand mechanisms underlying cardiac fibrosis and to assess new treatment strategies. Improving the appropriate applications of CMR to mouse studies of cardiac fibrosis has the potential to generate new knowledge, and more accurately examine the safety and efficacy of antifibrotic therapies. In this review, we provide 1) a brief overview of different types of cardiac fibrosis, 2) general background on magnetic resonance imaging (MRI), 3) a summary of different CMR techniques used in mice for the assessment of cardiac fibrosis including experimental and technical considerations (contrast agents and pulse sequences), and 4) provide an overview of mouse studies that have serially monitored cardiac fibrosis during disease progression and/or therapeutic interventions. Clinically established CMR protocols have advanced mouse CMR for the detection of cardiac fibrosis, and there is hope that discovery studies in mice will identify new antifibrotic therapies for patients, highlighting the value of both reverse translation and bench-to-bedside research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
183. Deletion of the muscle enriched lncRNA Oip5os1 induces atrial dysfunction in male mice with diabetes.
- Author
-
Zhuang, Aowen, Tan, Yanie, Liu, Yingying, Yang, Christine, Kiriazis, Helen, Grigolon, Kyah, Walker, Shannen, Bond, Simon T., McMullen, Julie R., Calkin, Anna C., and Drew, Brian G.
- Subjects
- *
LEFT ventricular dysfunction , *LINCRNA , *MYOCARDIUM , *DIABETES , *STRIATED muscle - Abstract
Long ncRNAs (lncRNAs) have been shown to play a biological and physiological role in various tissues including the heart. We and others have previously established that the lncRNA Oip5os1 (1700020I14Rik, OIP5‐AS1, Cyrano) is enriched in striated muscles, and its deletion in mice leads to defects in both skeletal and cardiac muscle function. In the present study, we investigated the impact of global Oip5os1 deletion on cardiac function in the setting of streptozotocin (STZ)‐induced diabetes. Specifically, we studied male WT and KO mice with or without diabetes for 24 weeks, and phenotyped animals for metabolic and cardiac endpoints. Independent of genotype, diabetes was associated with left ventricular diastolic dysfunction based on a fall in E'/A' ratio. Deletion of Oip5os1 in a setting of diabetes had no significant impact on ventricular function or ventricular weight, but was associated with left atrial dysfunction (reduced fractional shortening) and myopathy which was associated with anesthesia intolerance and premature death in the majority of KO mice tested during cardiac functional assessment. This atrial phenotype was not observed in WT diabetic mice. The most striking molecular difference was a reduction in the metabolic regulator ERRalpha in the atria of KO mice compared with WT mice. There was also a trend for a reduction in Serca2a. These findings highlight Oip5os1 as a gene of interest in aspects of atrial function in the setting of diabetes, highlighting an additional functional role for this lncRNA in cardiac pathological settings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
184. Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload.
- Author
-
Bernardo, Bianca C., Nguyen, Sally S., Gao, Xiao-Ming, Tham, Yow Keat, Ooi, Jenny Y. Y., Patterson, Natalie L., Kiriazis, Helen, Su, Yidan, Thomas, Colleen J., Lin, Ruby C. Y., Du, Xiao-Jun, and McMullen, Julie R.
- Published
- 2016
- Full Text
- View/download PDF
185. Smad7gene delivery prevents muscle wasting associated with cancer cachexia in mice
- Author
-
Winbanks, Catherine E., Murphy, Kate T., Bernardo, Bianca C., Qian, Hongwei, Liu, Yingying, Sepulveda, Patricio V., Beyer, Claudia, Hagg, Adam, Thomson, Rachel E., Chen, Justin L., Walton, Kelly L., Loveland, Kate L., McMullen, Julie R., Rodgers, Buel D., Harrison, Craig A., Lynch, Gordon S., and Gregorevic, Paul
- Abstract
Muscle-directed Smad7gene delivery prevents the loss of skeletal muscle mass and strength in mouse models of cachexia, an important contributor to poor prognosis in patients with advanced cancer.
- Published
- 2016
- Full Text
- View/download PDF
186. Abstract 58.
- Author
-
Ooi, Jenny Y, Bernardo, Bianca C, Boey, Esther J, Lin, Ruby C, and McMullen, Julie R
- Published
- 2014
187. Abstract 50.
- Author
-
Bernardo, Bianca C, Nguyen, Sally S, Winbanks, Catherine E, Gao, Xiao-Ming, Boey, Esther J, Tham, Yow Keat, Kiriazis, Helen, Thomas, Colleen J, Lin, Ruby C, Du, Xiao-Jun, and McMullen, Julie R
- Published
- 2014
188. The yin and yang of adaptive and maladaptive processes in heart failure.
- Author
-
Bernardo, Bianca C., Ooi, Jenny Y.Y., and McMullen, Julie R.
- Subjects
HEART failure ,BLOOD pressure ,HEART cells ,MYOCARDIAL infarction ,HEMODYNAMICS ,AUTOPHAGY - Abstract
The heart is continuously faced with a dynamic workload and is able to respond by modifying its size and shape. In response to acute hemodynamic loads (e.g. short term increases in blood pressure) or conditions that place a physiologic load on the heart (e.g. exercise, pregnancy), the heart is able to adapt and maintain cardiac function. However, a sustained pathological stress such as chronic pressure overload or myocardial infarction, leads to a maladaptive form of heart growth and the heart ultimately fails. Here we discuss the features of adaptive and maladaptive heart growth, the dysregulation of processes involved with the transition to heart failure (e.g. angiogenesis, autophagy), and the regulation of signaling pathways and genes in different cardiac cells (e.g. myocytes, fibroblasts, vascular and inflammatory cells). Finally, we discuss novel therapeutic approaches for heart failure which target adaptive processes in the heart. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
189. Abstract 315.
- Author
-
Huynh, Karina, Kiriazis, Helen, Du, Xiao-Jun, Love, Jane E, Jandeleit-Dahm, Karin, McMullen, Julie R, and Ritchie, Rebecca H
- Published
- 2012
190. Modulation of TLR2 induces cardioprotection through a Phosphoinositide 3- Kinase Dependent Mechanism.
- Author
-
Tuanzhu Ha, Fang Hua, Jing Ma, Kelley, Jim L., McMullen, Julie R., Tetsuo Shioi, Izumo, Seigo, Browder, I. William, Kao, Race L., Williams, David L., and Chuanfu Li
- Subjects
IMMUNOREGULATION ,GLUCANS ,ISCHEMIA ,MYOCARDIAL reperfusion ,PEPTIDOGLYCANS ,PHOSPHOINOSITIDES ,MYOCARDIAL infarction ,TRANSGENIC mice - Abstract
We have reported that the immune modulator, glucan, rapidly induces cardioprotection. TLR2 is required for glucan activation of cellular signaling. However, the role of TLR2 in cardioprotection has not been investigated. Peptidoglycan (PDG) activates cellular signaling specifically through TLR2. In this study we examined the effect of modulation of TLR2 on myocardial I/R injury. TLR2 KO (n=8) and wild type mice (n=8) were treated with PDG (100 fÝYg/25g) or glucan (1 mg/25g) one hr before the hearts were subjected to ischemia (1 hr)/reperfusion (4 hrs). Untreated mice (n=8) served as control. To investigate the role of PI3K/Akt in modulation of TLR2-induced cardioprotection, we administered PDG (100 fÝg/25g) or glucan (1 mg/25g) to kdAkt transgenic mice (n=8) one hr before I/R. Myocardial infarction was determined by TTC staining. Infarct size was significantly reduced in PDG (10.5 ¡Ó 3,03% vs 30.1 ¡Ó 7.59%, p<0.01) and glucan (11.6 ¡Ó 2.38% vs 36.1 ¡Ó 3.48%, p<0.01) treated mice vs untreated mice. Both PDG and glucan-induced cardioprotection were completely abolished in TLR2 KO mice. The cardioprotection induced by either direct (PDG) or indicate (glucan) modulation of TLR2 was also abolished in kdAkt mice. The results suggest that the mechanism of modulation of TLR2-induced cardioprotection is mediated through a PI3K/Akt dependent mechanism and that there is a link between TLR2 and PI3K/Akt signaling during I/R. [ABSTRACT FROM AUTHOR]
- Published
- 2007
191. In Vivo Inhibition of miR-34a Modestly Limits Cardiac Enlargement and Fibrosis in a Mouse Model with Established Type 1 Diabetes-Induced Cardiomyopathy, but Does Not Improve Diastolic Function.
- Author
-
Bernardo, Bianca C., Yildiz, Gunes S., Kiriazis, Helen, Harmawan, Claudia A., Tai, Celeste M. K., Ritchie, Rebecca H., and McMullen, Julie R.
- Subjects
- *
HEART fibrosis , *LABORATORY mice , *TYPE 1 diabetes , *ANIMAL disease models , *CARDIOMYOPATHIES - Abstract
MicroRNA 34a (miR-34a) is elevated in the heart in a setting of cardiac stress or pathology, and we previously reported that inhibition of miR-34a in vivo provided protection in a setting of pressure overload-induced pathological cardiac hypertrophy and dilated cardiomyopathy. Prior work had also shown that circulating or cardiac miR-34a was elevated in a setting of diabetes. However, the therapeutic potential of inhibiting miR-34a in vivo in the diabetic heart had not been assessed. In the current study, type 1 diabetes was induced in adult male mice with 5 daily injections of streptozotocin (STZ). At 8 weeks post-STZ, when mice had established type 1 diabetes and diastolic dysfunction, mice were administered locked nucleic acid (LNA)-antimiR-34a or saline-control with an eight-week follow-up. Cardiac function, cardiac morphology, cardiac fibrosis, capillary density and gene expression were assessed. Diabetic mice presented with high blood glucose, elevated liver and kidney weights, diastolic dysfunction, mild cardiac enlargement, cardiac fibrosis and reduced myocardial capillary density. miR-34a was elevated in the heart of diabetic mice in comparison to non-diabetic mice. Inhibition of miR-34a had no significant effect on diastolic function or atrial enlargement, but had a mild effect on preventing an elevation in cardiac enlargement, fibrosis and ventricular gene expression of B-type natriuretic peptide (BNP) and the anti-angiogenic miRNA (miR-92a). A miR-34a target, vinculin, was inversely correlated with miR-34a expression, but other miR-34a targets were unchanged. In summary, inhibition of miR-34a provided limited protection in a mouse model with established type 1 diabetes-induced cardiomyopathy and failed to improve diastolic function. Given diabetes represents a systemic disorder with numerous miRNAs dysregulated in the diabetic heart, as well as other organs, strategies targeting multiple miRNAs and/or earlier intervention is likely to be required. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
192. Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity.
- Author
-
Abdellatif, Mahmoud, Trummer-Herbst, Viktoria, Heberle, Alexander Martin, Humnig, Alina, Pendl, Tobias, Durand, Sylvère, Cerrato, Giulia, Hofer, Sebastian J., Islam, Moydul, Voglhuber, Julia, Ramos Pittol, José Miguel, Kepp, Oliver, Hoefler, Gerald, Schmidt, Albrecht, Rainer, Peter P., Scherr, Daniel, von Lewinski, Dirk, Bisping, Egbert, McMullen, Julie R., and Diwan, Abhinav
- Subjects
- *
SOMATOMEDIN C , *INSULIN-like growth factor receptors , *LONGEVITY , *CELLULAR aging , *AGING , *EPIDERMAL growth factor receptors , *PHOSPHATIDYLINOSITOL 3-kinases , *CELL metabolism , *SOMATOMEDIN , *PHOSPHOTRANSFERASES , *ANIMAL experimentation , *RESEARCH funding , *HEALTH promotion , *MICE , *ANIMALS - Abstract
Background: The insulin-like growth factor 1 (IGF1) pathway is a key regulator of cellular metabolism and aging. Although its inhibition promotes longevity across species, the effect of attenuated IGF1 signaling on cardiac aging remains controversial.Methods: We performed a lifelong study to assess cardiac health and lifespan in 2 cardiomyocyte-specific transgenic mouse models with enhanced versus reduced IGF1 receptor (IGF1R) signaling. Male mice with human IGF1R overexpression or dominant negative phosphoinositide 3-kinase mutation were examined at different life stages by echocardiography, invasive hemodynamics, and treadmill coupled to indirect calorimetry. In vitro assays included cardiac histology, mitochondrial respiration, ATP synthesis, autophagic flux, and targeted metabolome profiling, and immunoblots of key IGF1R downstream targets in mouse and human explanted failing and nonfailing hearts, as well.Results: Young mice with increased IGF1R signaling exhibited superior cardiac function that progressively declined with aging in an accelerated fashion compared with wild-type animals, resulting in heart failure and a reduced lifespan. In contrast, mice with low cardiac IGF1R signaling exhibited inferior cardiac function early in life, but superior cardiac performance during aging, and increased maximum lifespan, as well. Mechanistically, the late-life detrimental effects of IGF1R activation correlated with suppressed autophagic flux and impaired oxidative phosphorylation in the heart. Low IGF1R activity consistently improved myocardial bioenergetics and function of the aging heart in an autophagy-dependent manner. In humans, failing hearts, but not those with compensated hypertrophy, displayed exaggerated IGF1R expression and signaling activity.Conclusions: Our findings indicate that the relationship between IGF1R signaling and cardiac health is not linear, but rather biphasic. Hence, pharmacological inhibitors of the IGF1 pathway, albeit unsuitable for young individuals, might be worth considering in older adults. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
193. Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways.
- Author
-
Huynh, Karina, Bernardo, Bianca C., McMullen, Julie R., and Ritchie, Rebecca H.
- Subjects
- *
DIABETIC cardiomyopathy , *THERAPEUTIC use of antioxidants , *CELLULAR signal transduction , *CARDIOVASCULAR disease treatment , *CLINICAL trials , *PEOPLE with diabetes , *MICROCIRCULATION disorders ,CARDIOVASCULAR disease related mortality - Abstract
Abstract: Cardiovascular disease is the primary cause of morbidity and mortality among the diabetic population. Both experimental and clinical evidence suggest that diabetic subjects are predisposed to a distinct cardiomyopathy, independent of concomitant macro- and microvascular disorders. ‘Diabetic cardiomyopathy’ is characterized by early impairments in diastolic function, accompanied by the development of cardiomyocyte hypertrophy, myocardial fibrosis and cardiomyocyte apoptosis. The pathophysiology underlying diabetes-induced cardiac damage is complex and multifactorial, with elevated oxidative stress as a key contributor. We now review the current evidence of molecular disturbances present in the diabetic heart, and their role in the development of diabetes-induced impairments in myocardial function and structure. Our focus incorporates both the contribution of increased reactive oxygen species production and reduced antioxidant defenses to diabetic cardiomyopathy, together with modulation of protein signaling pathways and the emerging role of protein O-GlcNAcylation and miRNA dysregulation in the progression of diabetic heart disease. Lastly, we discuss both conventional and novel therapeutic approaches for the treatment of left ventricular dysfunction in diabetic patients, from inhibition of the renin–angiotensin–aldosterone-system, through recent evidence favoring supplementation of endogenous antioxidants for the treatment of diabetic cardiomyopathy. Novel therapeutic strategies, such as gene therapy targeting the phosphoinositide 3-kinase PI3K(p110α) signaling pathway, and miRNA dysregulation, are also reviewed. Targeting redox stress and protective protein signaling pathways may represent a future strategy for combating the ever-increasing incidence of heart failure in the diabetic population. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
194. Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure.
- Author
-
Yang, Kai-Chien, Jay, Patrick Y., McMullen, Julie R., and Nerbonne, Jeanne M.
- Subjects
- *
HYPERTROPHY , *HEART failure , *CELLULAR signal transduction , *ARRHYTHMIA , *PHOSPHOINOSITIDES , *ELECTROPHYSIOLOGY , *LABORATORY mice - Abstract
Aims Cardiac hypertrophy and heart failure are associated with QT prolongation and lethal ventricular arrhythmias resulting from decreased K+ current densities and impaired repolarization. Recent studies in mouse models of physiological cardiac hypertrophy revealed that increased phosphoinositide-3-kinase-α (PI3Kα) signalling results in the up-regulation of K+ channels and the normalization of ventricular repolarization. The experiments here were undertaken to test the hypothesis that increased PI3Kα signalling will counteract the adverse electrophysiological remodelling associated with pathological hypertrophy and heart failure. Methods and results In contrast to wild-type mice, left ventricular (LV) hypertrophy, induced by transverse aortic constriction (TAC), did not result in prolongation of ventricular action potentials or QT intervals in mice with cardiac-specific expression of constitutively active PI3Kα (caPI3Kα). Indeed, repolarizing K+ currents and K+ channel subunit transcripts were increased in caPI3Kα + TAC LV myocytes in proportion to the TAC-induced cellular hypertrophy. Congestive heart failure in a transgenic model of dilated cardiomyopathy model is accompanied by prolonged QT intervals and ventricular action potentials, reduced K+ currents and K+ channel transcripts. Increased PI3Kα signalling, but not renin–angiotensin system blockade, in this model also results in increased K+ currents and improved ventricular repolarization. Conclusion In the setting of pathological hypertrophy or heart failure, enhanced PI3Kα signalling results in the up-regulation of K+ channel subunits, normalization of K+ current densities and preserved ventricular function. Augmentation of PI3Kα signalling, therefore, may be a useful and unique strategy to protect against the increased risk of ventricular arrhythmias and sudden death associated with cardiomyopathy. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
195. Overexpression of Heat Shock Protein 70 Improves Cardiac Remodeling and Survival in Protein Phosphatase 2A-Expressing Transgenic Mice with Chronic Heart Failure.
- Author
-
Yoon, Somy, Gergs, Ulrich, McMullen, Julie R., and Eom, Gwang Hyeon
- Subjects
- *
TRANSGENIC mice , *PHOSPHOPROTEIN phosphatases , *HEAT shock proteins , *GENETIC overexpression , *HEART failure , *POST-translational modification - Abstract
Heat shock protein (HSP) 70 is a molecular chaperone that regulates protein structure in response to thermal stress. In addition, HSP70 is involved in post-translational modification and is related to the severity of some diseases. Here, we tested the functional relevance of long-lasting HSP70 expression in a model of nonischemic heart failure using protein phosphatase 2 catalytic subunit A (PP2CA)-expressing transgenic mice. These transgenic mice, with cardiac-specific overexpression of PP2CA, abruptly died after 12 weeks of postnatal life. Serial echocardiograms to assess cardiac function revealed that the ejection fraction (EF) was gradually decreased in transgenic PP2CA (TgPP2CA) mice. In addition, PP2CA expression exacerbated systolic dysfunction and LV dilatation, with free wall thinning, which are indicators of fatal dilated cardiomyopathy. Interestingly, simultaneous expression of HSP70 in double transgenic mice (dTg) significantly improved the dilated cardiomyopathy phenotype of TgPP2CA mice. We observed better survival, preserved EF, reduced chamber enlargement, and suppression of free wall thinning. In the proposed molecular mechanism, HSP70 preferentially regulates the phosphorylation of AKT. Phosphorylation of AKT was significantly reduced in TgPP2CA mice but was not significantly lower in dTg mice. Signal crosstalk between AKT and its substrates, in association with HSP70, might be a useful intervention for patients with nonischemic heart failure to suppress cardiac remodeling and improve survival. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
196. Prevention of Pathological Atrial Remodeling and Atrial Fibrillation: JACC State-of-the-Art Review.
- Author
-
Chen, Yi Ching, Voskoboinik, Aleksandr, Gerche, Andre La, Marwick, Thomas H., and McMullen, Julie R.
- Subjects
- *
ATRIAL fibrillation , *ATHLETES , *PREGNANT women , *ENDURANCE sports , *MITRAL valve , *KNOWLEDGE gap theory , *ATRIAL fibrillation prevention , *HUMAN reproduction , *PREGNANCY , *HEART diseases , *ANIMALS - Abstract
Atrial enlargement in response to pathological stimuli (e.g., hypertension, mitral valve disease) and physiological stimuli (exercise, pregnancy) can be comparable in magnitude, but the diseased enlarged atria is associated with complications such as atrial fibrillation (AF), whereas physiological atrial enlargement is not. Pathological atrial enlargement and AF is also observed in a small percentage of athletes undergoing extreme/intense endurance sport and pregnant women with preeclampsia. Differences between physiological and pathological atrial enlargement and underlying mechanisms are poorly understood. This review describes human and animal studies characterizing atrial enlargement under physiological and pathological conditions and highlights key knowledge gaps and clinical challenges, including: 1) the limited ability of atria to reverse remodel; and 2) distinguishing physiological and pathological enlargement via imaging/biomarkers. Finally, this review discusses how targeting distinct molecular mechanisms underlying physiological and pathological atrial enlargement could provide new therapeutic and diagnostic strategies for preventing or reversing atrial enlargement and AF. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
197. FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K
- Author
-
Weeks, Kate L., Tham, Yow Keat, Yildiz, Suzan G., Alexander, Yonali, Donner, Daniel G., Kiriazis, Helen, Harmawan, Claudia A., Hsu, Amy, Bernardo, Bianca C., Aya Matsumoto, DePinho, Ronald A., Dale Abel, E., Woodcock, Elizabeth A., and McMullen, Julie R.
- Abstract
The insulin-like growth factor 1 receptor (IGF1R) and phosphoinositide 3-kinase p110α (PI3K) are critical regulators of exercise-induced physiological cardiac hypertrophy and provide protection in experimental models of pathological remodeling and heart failure. Forkhead box class O1 (FoxO1) is a transcription factor that regulates cardiomyocyte hypertrophy downstream of IGF1R/PI3K activation in vitro, but its role in physiological hypertrophy in vivo was unknown. We generated cardiomyocyte-specific FoxO1 knockout (cKO) mice and assessed the phenotype under basal conditions and settings of physiological hypertrophy induced by 1) swim training or 2) cardiac-specific transgenic expression of constitutively active PI3K (caPI3KTg+). Under basal conditions, male and female cKO mice displayed mild interstitial fibrosis compared with control (CON) littermates, but no other signs of cardiac pathology were present. In response to exercise training, female CON mice displayed an increase (∼21%) in heart weight normalized to tibia length vs. untrained mice. Exercise-induced hypertrophy was blunted in cKO mice. Exercise increased cardiac Akt phosphorylation and IGF1R expression but was comparable between genotypes. However, differences in Foxo3a, Hsp70, and autophagy markers were identified in hearts of exercised cKO mice. Deletion of FoxO1 did not reduce cardiac hypertrophy in male or female caPI3KTg+ mice. Cardiac Akt and FoxO1 protein expressions were significantly reduced in hearts of caPI3KTg+ mice, which may represent a negative feedback mechanism from chronic caPI3K, and negate any further effect of reducing FoxO1 in the cKO. In summary, FoxO1 contributes to exercise-induced hypertrophy. This has important implications when one is considering FoxO1 as a target for treating the diseased heart.NEW & NOTEWORTHY Regulators of exercise-induced physiological cardiac hypertrophy and protection are considered promising targets for the treatment of heart failure. Unlike pathological hypertrophy, the transcriptional regulation of physiological hypertrophy has remained largely elusive. To our knowledge, this is the first study to show that the transcription factor FoxO1 is a critical mediator of exercise-induced cardiac hypertrophy. Given that exercise-induced hypertrophy is protective, this finding has important implications when one is considering FoxO1 as a target for treating the diseased heart. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
198. Exercise training reveals micro-RNAs associated with improved cardiac function and electrophysiology in rats with heart failure after myocardial infarction.
- Author
-
Stølen, Tomas O., Høydal, Morten A., Ahmed, Muhammad Shakil, Jørgensen, Kari, Garten, Karin, Hortigon-Vinagre, Maria P., Zamora, Victor, Scrimgeour, Nathan R., Berre, Anne Marie Ormbostad, Nes, Bjarne M., Skogvoll, Eirik, Johnsen, Anne Berit, Moreira, Jose B.N., McMullen, Julie R., Attramadal, Håvard, Smith, Godfrey L., Ellingsen, Øyvind, and Wisløff, Ulrik
- Subjects
- *
HIGH-intensity interval training , *MYOCARDIAL infarction , *MICRORNA , *HEART failure , *INDUCED pluripotent stem cells , *LEFT heart ventricle , *ELECTROPHYSIOLOGY , *MOTIVATIONAL interviewing - Abstract
Endurance training improves aerobic fitness and cardiac function in individuals with heart failure. However, the underlying mechanisms are not well characterized. Exercise training could therefore act as a tool to discover novel targets for heart failure treatment. We aimed to associate changes in Ca2+ handling and electrophysiology with micro-RNA (miRNA) profile in exercise trained heart failure rats to establish which miRNAs induce heart failure-like effects in Ca2+ handling and electrophysiology. Post-myocardial infarction (MI) heart failure was induced in Sprague Dawley rats. Rats with MI were randomized to sedentary control (sed), moderate (mod)- or high-intensity (high) endurance training for 8 weeks. Exercise training improved cardiac function, Ca2+ handling and electrophysiology including reduced susceptibility to arrhythmia in an exercise intensity-dependent manner where high intensity gave a larger effect. Fifty-five miRNAs were significantly regulated (up or down) in MI-sed, of which 18 and 3 were changed towards Sham-sed in MI-high and MI-mod, respectively. Thereafter we experimentally altered expression of these "exercise-miRNAs" individually in human induced pluripotent stem cell-derived cardiomyocytes (hIPSC-CM) in the same direction as they were changed in MI. Of the "exercise-miRNAs", miR-214-3p prolonged AP duration, whereas miR-140 and miR-208a shortened AP duration. miR-497-5p prolonged Ca2+ release whereas miR-214-3p and miR-31a-5p prolonged Ca2+ decay. Using exercise training as a tool, we discovered that miR-214-3p, miR-497-5p, miR-31a-5p contribute to heart-failure like behaviour in Ca2+ handling and electrophysiology and could be potential treatment targets. Unlabelled Image • High intensity exercise is superior to moderate intensity on reducing propensity for ventricular fibrillation. • Magnitude of improvements in Ca2+ handling and electrophysiological properties are exercise intensity dependent. • 55 miRNAs were changed in the left ventricle of failing hearts. • High intensity exercise training restored or partly restored 18 of the 55 miRNA. • Of these, miR-214-3p, miR-497-5p, miR-31a-5p caused impaired Ca2+ handling and electrophysiology in hIPSC-CMs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
199. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes.
- Author
-
Prakoso, Darnel, De Blasio, Miles J., Tate, Mitchel, Kiriazis, Helen, Donner, Daniel G., Hongwei Qian, Nash, David, Minh Deo, Weeks, Kate L., Parry, Laura J., Gregorevic, Paul, McMullen, Julie R., and Ritchie, Rebecca Helen
- Subjects
- *
TYPE 2 diabetes , *GENE therapy , *GENE targeting , *DIABETIC cardiomyopathy , *PEOPLE with diabetes , *PHOSPHOINOSITIDES - Abstract
Diabetic cardiomyopathy is a distinct form of heart disease that represents a major cause of death and disability in diabetic patients, particularly, the more prevalent type 2 diabetes patient population. In the current study, we investigated whether administration of recombinant adeno-associated viral vectors carrying a constitutively active phosphoinositide 3-kinase (PI3K)(p110α) construct (rAAV6-caPI3K) at a clinically relevant time point attenuates diabetic cardiomyopathy in a preclinical type 2 diabetes (T2D) model. T2D was induced by a combination of a high-fat diet (42% energy intake from lipid) and low-dose streptozotocin (three consecutive intraperitoneal injections of 55 mg/kg body wt), and confirmed by increased body weight, mild hyperglycemia, and impaired glucose tolerance (all P < 0.05 vs. nondiabetic mice). After 18 wk of untreated diabetes, impaired left ventricular (LV) systolic dysfunction was evident, as confirmed by reduced fractional shortening and velocity of circumferential fiber shortening (Vcfc, all P < 0.01 vs. baseline measurement). A single tail vein injection of rAAV6-caPI3K gene therapy (21011vector genomes) was then administered. Mice were followed for an additional 8 wk before end point. A single injection of cardiac targeted rAAV6- caPI3K attenuated diabetes-induced cardiac remodeling by limiting cardiac fibrosis (reduced interstitial and perivascular collagen deposition, P < 0.01 vs. T2D mice) and cardiomyocyte hypertrophy (reduced cardiomyocyte size and Nppa gene expression, P < 0.001 and P < 0.05 vs. T2D mice, respectively). The diabetes-induced LV systolic dysfunction was reversed with rAAV6-caPI3K, as demonstrated by improved fractional shortening and velocity of circumferential fiber shortening (all P < 0.05 vs pre-AAV measurement). This cardioprotection occurred in combination with reduced LV reactive oxygen species (P < 0.05 vs. T2D mice) and an associated decrease in markers of endoplasmic reticulum stress (reduced Grp94 and Chop, all P < 0.05 vs. T2D mice). Together, our findings demonstrate that a cardiac-selective increase in PI3K(p110α), via rAAV6-caPI3K, attenuates T2D-induced diabetic cardiomyopathy, providing proof of concept for potential translation to the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
200. Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure.
- Author
-
Bass-Stringer, Sebastian, Bernardo, Bianca C., May, Clive N., Thomas, Colleen J., Weeks, Kate L., and McMullen, Julie R.
- Subjects
- *
HEART failure treatment , *ADENO-associated virus , *GENE therapy , *PUBLIC health , *CAUSES of death , *ANIMALS , *BIOLOGICAL models , *GENES , *GENETIC techniques , *VIRUSES - Abstract
Despite advances in treatment over the past decade, heart failure remains a significant public health burden and a leading cause of death in the developed world. Gene therapy provides a promising approach for preventing and reversing cardiac abnormalities, however, clinical application has shown limited success to date. A substantial effort is being invested into the development of recombinant adeno-associated viruses (AAVs) for cardiac gene therapy as AAV gene therapy offers a high safety profile and provides sustained and efficient transgene expression following a once-off administration. Due to the physiological, anatomical and genetic similarities between large animals and humans, preclinical studies using large animal models for AAV gene therapy are crucial stepping stones between the laboratory and the clinic. Many molecular targets selected to treat heart failure using AAV gene therapy have been chosen because of their potential to regulate and restore cardiac contractility. Other genes targeted with AAV are involved with regulating angiogenesis, beta-adrenergic sensitivity, inflammation, physiological signalling and metabolism. While significant progress continues to be made in the field of AAV cardiac gene therapy, challenges remain in overcoming host neutralising antibodies, improving AAV vector cardiac-transduction efficiency and selectivity, and optimising the dose, route and method of delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.